SAHPRA Approves Pfizer’s Paxlovid COVID-19 Treatment
SAHPRA announced the registration of Paxlovid COVID-19 treatment, an anti-viral medicine manufactured by Pfizer, to treat COVID-19. This is a 5-day oral treatment for mild to moderate COVID-19 in adults who do not require supplemental oxygen and who are at increased risk for progression to severe COVID-19.
International sources provide guidelines regarding prescribing in liver and kidney disease as well as possible drug interactions including statin therapy, anticoagulation and some hormonal birth control treatments.
Recent Posts
Sandoz Mobile Health Initiative: Empowering Communities Through Accessible Care
Sandoz has launched the Sandoz mobile health initiative in Portugal through its “Sandoz em Marcha” project, sending a mobile health unit to 16 localities over two months to deliver free screenings and health educ...
Strategic Investment Boosts Medical Device Distribution in Africa
Amethis, Proparco, ccap.ai and Vertice management have completed the acquisition of Vertice MedTech Holdings, positioning the company for accelerated expansion as the ...
Navigating the Challenges of Patient-Centered AI Systems in Postpartum Depression Care
Patient-centered AI systems can improve care, but moving them from labs to clinics without causing harm remains a critical challenge. A recent qualitative study explored this question by capturing the perspectives of patients, healthcare professionals, and developers, using a postpartum depressio...